The limited size of patients in the with CD20 negative group do not allow for any definitive conclusions, and further studies are warranted to investigate if CD20 loss on tumor cells is indeed associated with poorer outcomes in patients with relapse or refractory follicular lymphoma. Here, MS4A1 is linked to follicular lymphoma.